Tumor necrosis factor and Lymphotoxin-alpha (TNF and LTA)

Tumor necrosis factor (TNF, formerly TNF-alpha) and Lymphotoxin-alpha (LTA, formerly TNF-beta) are potent pro-inflammatory cytokines belonging to the TNF superfamily (UniProt P01375; UniProt P01374). TNF is primarily produced by macrophages and T-cells, playing a central role in the orchestration of the innate and adaptive immune responses by inducing the production of other cytokines and adhesion molecules (StatPearls, TNF Inhibitors). LTA is produced by activated lymphocytes and shares significant structural homology with TNF, allowing both to bind to the same cell surface receptors, TNFR1 and TNFR2 (PMID: 14502271). Dysregulation and overproduction of these cytokines are implicated in the pathogenesis of numerous chronic inflammatory and autoimmune disorders, including rheumatoid arthritis, plaque psoriasis, and inflammatory bowel disease (StatPearls, TNF Inhibitors). Therapeutic intervention typically involves the use of monoclonal antibodies or soluble receptor fusion proteins that neutralize these cytokines to reduce systemic inflammation (StatPearls, TNF Inhibitors). While highly effective, inhibition of TNF and LTA can lead to significant safety concerns, such as an increased susceptibility to opportunistic infections like tuberculosis and a potential risk for certain malignancies (StatPearls, TNF Inhibitors).

Other names

Tumor necrosis factor alphaTNF-alphaCachectinTumor necrosis factor betaTNF-betaLymphotoxin-alphaLT-alphaTNFSF2TNFSF1

TNF inhibitors bind to and neutralize soluble and membrane-bound TNF-alpha and/or Lymphotoxin-alpha, preventing their interaction with TNFR1 and TNFR2 receptors and thereby inhibiting pro-inflammatory signaling pathways (StatPearls, TNF Inhibitors; PMID: 14502271).